Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD)
NCT ID: NCT01730170
Last Updated: 2023-07-13
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
565 participants
Study Classification
OBSERVATIONAL
Study Start Date
2013-01-31
Study Completion Date
2022-12-12
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Epilepsy is one of the most common neurological disorders affecting women of childbearing age. Poor pregnancy outcomes are increased in these women and their children. The proposed studies will increase our knowledge on multiple levels to improve care and reduce adverse outcomes in these mothers and children. An overall goal of this study is to establish the relationship between antiepileptic drug exposure and outcomes in the mother and child as well as describe and explain the variability in antiepileptic drug exposure and response.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Developmental Effects On Children Of Women Who Take Antiepileptic Drugs During Pregnancy
NCT00021866
Epilepsy
Seizure
Cognition Disorders
COMPLETED
Study of Antiepileptic Drug Effects on Child Development
NCT00353886
Epilepsy
COMPLETED
Women With Epilepsy: Pregnancy Outcomes and Deliveries
NCT01259310
Epilepsy
COMPLETED
UCB Antiepileptic Drugs (AED) Pregnancy Registry (Formerly the Keppra® Pregnancy Registry)
NCT00345475
Birth Defects
Pregnancy Complications
Epilepsy
+1 more
COMPLETED
Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies
NCT05364021
Developmental and Epileptic Encephalopathy
Dravet Syndrome
Lennox Gastaut Syndrome
COMPLETED
PHASE1/PHASE2
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
There is a compelling need for prospective, properly controlled studies in women with epilepsy (WWE) during pregnancy to improve maternal and child outcomes. The proposed investigations are pertinent to the National Institute of Neurological Disorders and Stroke Epilepsy Research Benchmarks and will address multiple gaps in our knowledge noted by the recent American Academy of Neurology guidelines. This multicenter investigation will employ a prospective, observational, parallel-group, cohort design with an established research team.
The specific aims are to:
1. Determine if women with epilepsy have increased seizures during pregnancy and delineate the contributing factors;
2. Determine if C-section rate is increased in women with epilepsy and delineate contributing factors;
3. Determine if women with epilepsy have an increased risk for depression during pregnancy and post-partum period and characterize risks factors;
4. Determine the long-term effects of in utero antiepileptic drug exposure on verbal intellectual abilities and other neurobehavioral outcomes in the children of women with epilepsy;
5. Determine if small for gestation age and other adverse neonatal outcomes are increased in children of women with epilepsy;
6. Determine if breastfeeding when taking antiepileptic drugs impairs the child's verbal intellectual and other cognitive abilities.
An overall goal of the proposed research is to establish the relationship between antiepileptic drug exposure and outcomes in the mother and child as well as describe and explain the variability in antiepileptic drug exposure and response.
Anticonvulsant blood levels (ABLs) and area-under-the-concentration-time-curves (AUCs) will be used as direct measures of drug exposure. The results will enable clinicians to prospectively calculate individual dosing regimens for the mother in order to optimize dosing and limit unnecessary drug exposure to the child. In addition, genetic samples will be collected, which will provide a valuable resource for future pharmacogenetics studies to further delineate individual variability across patients.
FACTORS ASSESSED IN MONEAD.
Maternal factors: IQ, age, education, employment, ethnic group, maternal and family medical history including prior pregnancies and psychiatric disorders, socioeconomic status, site, periconception and pregnancy folate, concomitant medications, alcohol use, tobacco use, or other drug use during pregnancy, unwanted pregnancy, pregnancy complications, medical diseases and serious adverse events, McMaster Family Assessment Device (FAD), Block Food Frequency, and for WWE: types and frequency of seizures or epilepsy, antiepileptic drug dosages \& blood levels, and compliance.
Depression during pregnancy and post-partum as determined by the screening instrument (Beck Depression Inventory-II; BDI-II), the EPDS (Edinburgh Postnatal Depression Scale) and confirmed by the Structured Clinical Interview for DSM-IV (SCID), Beck Anxiety Inventory (BAI), Pittsburgh Sleep Index, and Perceived Stress Scale in mothers, Parental Stress Index, and Neurological Disorders Depression Inventory in Epilepsy (NDDI-E).
Maternal hormones (estradiol, progesterone) and Vit D will be drawn at Visit 1, 2, 3, 4, 5, 6 and 7. Maternal continine Levels will be collected via urine sample at Visit 3 on all non-smoking mothers. If the continine result is positive for tobacco smoke exposure, an LC/MS (liquid chromatography/mass spectrometry test.
Paternal \& relative factors: In fathers and a primary maternal relative, the following were collected: head circumference, IQ estimates, socioeconomic status, dob, race, ethnicity, family history, and medical history. For the father, marital status, total household income, employment status. weight, height, and handedness were also collected.
Adult IQ Assessments:
Peabody Picture Vocabulary Test (PPVT), Wechsler's Adult Intelligence Scale (WAIS).
Child factors: enrollment \& birth gestational ages, birthweight, breastfeeding, AED levels when breastfeeding, physical examinations, childhood medical diseases (including congenital malformations), head circumference, weight, serious adverse events, developmental delays, and special education. Also, obtained premature delivery, APGARs (1 \& 5 minutes), Neonatal Intensive Care Unit admissions and all admissions \>12hrs, hypoglycemia (\<45), need for resuscitation, and neonatal death. Child Hgb, Hct, PKU, TSH, and T4 at delivery from med records if collected.
Child Cognitive/Behavioral Assessments:
Denver II, Behavior Assessment System for Children - Parent (BASCP-2) and Teacher (BASCT-2), Behavior Rating Inventory of Executive Functioning Preschool (BRIEFP) and version 2 (BRIEF-2), Adaptive Behavior Assessment Scale 3 (ABAS-3), Modified Checklist for Autism in Toddlers (M-CHAT), Modified Edinburgh Handedness Inventory, Gilliam Autism Rating Scale 3 (GARS-3), Bayley Scales of Infant and Toddler Development-3 (BSID-III), Differential Abilities Scale-II (DAS-II), Preschool Language Scale-5 (PLS-5), Peabody Picture Vocabulary Test-4 (PPVT-4), Beery-Buktenica Developmental Test of Visual-Motor Integration-6 (VMI-6), Torrance Test of Creative Thinking- Figural (TTCT-F), NEuroPSYchological Assessment 2nd edition (NEPSY2), Expressive One Word Picture Vocabulary Test-4 (EOWPVT4), Wechsler's Intelligence Scale for Children 5 (WISC5) Coding subtest, Children's Memory Scale (CMS), Lafayette Grooved Pegboard (GPB), Wide Range Achievement Test 5th edition (WRAT5), and Social Responsiveness Scale 2
Verbal intellectual ability at age 6 years is the ultimate primary outcome. It is determined by Verbal Index which is average of Word Definitions and Verbal Similarities subtests from the Differential Ability Scales-2nd ed. (DAS-II),50 -School Age Level, Expressive One-Word Picture Vocabulary Test-4,51 the Phonological Processing, Comprehension of Instructions and Sentence Repetition subscales from the NEPSY-2 57 and the Peabody Picture Vocabulary Test-4th ed. (PPVT-4).52 Children will not reach age 6 in this initial grant period, so primary outcome at age 2 will be the Language Scale from the Bayley Scales of Infant \& Toddler Development-III.
Cerebral Lateralization will be assessed as verbal minus non-verbal difference scores and proportion of dextrals in PWWE vs. HPW and in their children as assessed by the Edinburgh Handedness Inventory.
The specific aims are to:
1. Determine if women with epilepsy have increased seizures during pregnancy and delineate the contributing factors;
2. Determine if C-section rate is increased in women with epilepsy and delineate contributing factors;
3. Determine if women with epilepsy have an increased risk for depression during pregnancy and post-partum period and characterize risks factors;
4. Determine the long-term effects of in utero antiepileptic drug exposure on verbal intellectual abilities and other neurobehavioral outcomes in the children of women with epilepsy;
5. Determine if small for gestation age and other adverse neonatal outcomes are increased in children of women with epilepsy;
6. Determine if breastfeeding when taking antiepileptic drugs impairs the child's verbal intellectual and other cognitive abilities.
An overall goal of the proposed research is to establish the relationship between antiepileptic drug exposure and outcomes in the mother and child as well as describe and explain the variability in antiepileptic drug exposure and response.
Anticonvulsant blood levels (ABLs) and area-under-the-concentration-time-curves (AUCs) will be used as direct measures of drug exposure. The results will enable clinicians to prospectively calculate individual dosing regimens for the mother in order to optimize dosing and limit unnecessary drug exposure to the child. In addition, genetic samples will be collected, which will provide a valuable resource for future pharmacogenetics studies to further delineate individual variability across patients.
FACTORS ASSESSED IN MONEAD.
Maternal factors: IQ, age, education, employment, ethnic group, maternal and family medical history including prior pregnancies and psychiatric disorders, socioeconomic status, site, periconception and pregnancy folate, concomitant medications, alcohol use, tobacco use, or other drug use during pregnancy, unwanted pregnancy, pregnancy complications, medical diseases and serious adverse events, McMaster Family Assessment Device (FAD), Block Food Frequency, and for WWE: types and frequency of seizures or epilepsy, antiepileptic drug dosages \& blood levels, and compliance.
Depression during pregnancy and post-partum as determined by the screening instrument (Beck Depression Inventory-II; BDI-II), the EPDS (Edinburgh Postnatal Depression Scale) and confirmed by the Structured Clinical Interview for DSM-IV (SCID), Beck Anxiety Inventory (BAI), Pittsburgh Sleep Index, and Perceived Stress Scale in mothers, Parental Stress Index, and Neurological Disorders Depression Inventory in Epilepsy (NDDI-E).
Maternal hormones (estradiol, progesterone) and Vit D will be drawn at Visit 1, 2, 3, 4, 5, 6 and 7. Maternal continine Levels will be collected via urine sample at Visit 3 on all non-smoking mothers. If the continine result is positive for tobacco smoke exposure, an LC/MS (liquid chromatography/mass spectrometry test.
Paternal \& relative factors: In fathers and a primary maternal relative, the following were collected: head circumference, IQ estimates, socioeconomic status, dob, race, ethnicity, family history, and medical history. For the father, marital status, total household income, employment status. weight, height, and handedness were also collected.
Adult IQ Assessments:
Peabody Picture Vocabulary Test (PPVT), Wechsler's Adult Intelligence Scale (WAIS).
Child factors: enrollment \& birth gestational ages, birthweight, breastfeeding, AED levels when breastfeeding, physical examinations, childhood medical diseases (including congenital malformations), head circumference, weight, serious adverse events, developmental delays, and special education. Also, obtained premature delivery, APGARs (1 \& 5 minutes), Neonatal Intensive Care Unit admissions and all admissions \>12hrs, hypoglycemia (\<45), need for resuscitation, and neonatal death. Child Hgb, Hct, PKU, TSH, and T4 at delivery from med records if collected.
Child Cognitive/Behavioral Assessments:
Denver II, Behavior Assessment System for Children - Parent (BASCP-2) and Teacher (BASCT-2), Behavior Rating Inventory of Executive Functioning Preschool (BRIEFP) and version 2 (BRIEF-2), Adaptive Behavior Assessment Scale 3 (ABAS-3), Modified Checklist for Autism in Toddlers (M-CHAT), Modified Edinburgh Handedness Inventory, Gilliam Autism Rating Scale 3 (GARS-3), Bayley Scales of Infant and Toddler Development-3 (BSID-III), Differential Abilities Scale-II (DAS-II), Preschool Language Scale-5 (PLS-5), Peabody Picture Vocabulary Test-4 (PPVT-4), Beery-Buktenica Developmental Test of Visual-Motor Integration-6 (VMI-6), Torrance Test of Creative Thinking- Figural (TTCT-F), NEuroPSYchological Assessment 2nd edition (NEPSY2), Expressive One Word Picture Vocabulary Test-4 (EOWPVT4), Wechsler's Intelligence Scale for Children 5 (WISC5) Coding subtest, Children's Memory Scale (CMS), Lafayette Grooved Pegboard (GPB), Wide Range Achievement Test 5th edition (WRAT5), and Social Responsiveness Scale 2
Verbal intellectual ability at age 6 years is the ultimate primary outcome. It is determined by Verbal Index which is average of Word Definitions and Verbal Similarities subtests from the Differential Ability Scales-2nd ed. (DAS-II),50 -School Age Level, Expressive One-Word Picture Vocabulary Test-4,51 the Phonological Processing, Comprehension of Instructions and Sentence Repetition subscales from the NEPSY-2 57 and the Peabody Picture Vocabulary Test-4th ed. (PPVT-4).52 Children will not reach age 6 in this initial grant period, so primary outcome at age 2 will be the Language Scale from the Bayley Scales of Infant \& Toddler Development-III.
Cerebral Lateralization will be assessed as verbal minus non-verbal difference scores and proportion of dextrals in PWWE vs. HPW and in their children as assessed by the Edinburgh Handedness Inventory.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Epilepsy
Pregnancy
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Pregnant Women without Epilepsy
Women in their first trimester of pregnancy who are not diagnosed with epilepsy
No interventions assigned to this group
Nonpregnant Women with Epilepsy
Women diagnosed with epilepsy and not currently pregnant.
No interventions assigned to this group
Pregnant Women with Epilepsy
Women in their first trimester of pregnancy and diagnosed with epilepsy
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Pregnant women with epilepsy up to 20 weeks gestation, healthy pregnant women without epilepsy up to 20 weeks gestation, or non-pregnant women with epilepsy.
* Ability to maintain a daily medical diary.
* Language skills in English or Spanish adequate to perform the cognitive tests and questionnaires.
* Access to a telephone for phone contacts.
* Age 14-45 inclusive.
Criteria applicable for non-pregnant women with epilepsy only:
* Minimum of 9 months post live birth, miscarriage, or elective termination.
* Not currently breastfeeding.
* The Father must be the biological father of the child in the study.
* The Maternal Relative must be a full biological relative or half-sibling of the mother chosen by the following hierarchy:
1. st choice: Sister of closest age to the mother in the trial
2. nd Sister of next closest age
3. rd Brother of closest age
4. th Brother of next closest age
5. th Mother
6. th Father of pregnant mother in the study
7. th Half-Sibling if NO Primary FULL relatives are available.
* Ability to maintain a daily medical diary.
* Language skills in English or Spanish adequate to perform the cognitive tests and questionnaires.
* Access to a telephone for phone contacts.
* Age 14-45 inclusive.
Criteria applicable for non-pregnant women with epilepsy only:
* Minimum of 9 months post live birth, miscarriage, or elective termination.
* Not currently breastfeeding.
* The Father must be the biological father of the child in the study.
* The Maternal Relative must be a full biological relative or half-sibling of the mother chosen by the following hierarchy:
1. st choice: Sister of closest age to the mother in the trial
2. nd Sister of next closest age
3. rd Brother of closest age
4. th Brother of next closest age
5. th Mother
6. th Father of pregnant mother in the study
7. th Half-Sibling if NO Primary FULL relatives are available.
Exclusion Criteria
* Women with an expected IQ\<70.
* IV drug use in past year or any of the following since the beginning of pregnancy: Alcohol abuse, cocaine, or methamphetamine) or sequelae of drug/alcohol abuse.
* History of psychogenic non-epileptic spells.
* History of positive Syphilis test.
* History of HIV positive test.
* Progressive cerebral disease (e.g., multiple sclerosis, progressive brain tumor).
* Presence of other major medical illness (e.g., diabetes, cancer).
* Any medical, psychiatric, or other condition that, in the judgment of the investigator, is a contraindication to protocol participation or impairs ability to give informed consent.
* Concurrent participation in an experimental drug trial.
* Exposure to known teratogens during pregnancy, excluding AEDs.
* Detection of fetal major congenital malformation prior to enrollment in current pregnancy.
* History of a known genetic disorder in herself or a primary relative (may contact MONEAD team with details for possible exception).
* Use of non-licensed midwife as primary source of natal care and/or planning home delivery or delivery at a stand-alone birth center, independent from a hospital.
-Planned surgical intervention for epilepsy that would occur during the subject's participation in the project
* Diagnosed by a health care professional as perimenopausal or postmenopausal.
* History of switching AEDs within 90 days of enrollment. "Switching" AEDs includes changing from no AED therapy to therapy, discontinuing a current AED therapy, or changing to a different AED therapy.
* Any medical, psychiatric, or other condition that, in the judgment of the investigator, is a contraindication to protocol participation or impairs ability to give informed consent.
* IV drug use in past year or any of the following since the beginning of pregnancy: Alcohol abuse, cocaine, or methamphetamine) or sequelae of drug/alcohol abuse.
* History of psychogenic non-epileptic spells.
* History of positive Syphilis test.
* History of HIV positive test.
* Progressive cerebral disease (e.g., multiple sclerosis, progressive brain tumor).
* Presence of other major medical illness (e.g., diabetes, cancer).
* Any medical, psychiatric, or other condition that, in the judgment of the investigator, is a contraindication to protocol participation or impairs ability to give informed consent.
* Concurrent participation in an experimental drug trial.
* Exposure to known teratogens during pregnancy, excluding AEDs.
* Detection of fetal major congenital malformation prior to enrollment in current pregnancy.
* History of a known genetic disorder in herself or a primary relative (may contact MONEAD team with details for possible exception).
* Use of non-licensed midwife as primary source of natal care and/or planning home delivery or delivery at a stand-alone birth center, independent from a hospital.
-Planned surgical intervention for epilepsy that would occur during the subject's participation in the project
* Diagnosed by a health care professional as perimenopausal or postmenopausal.
* History of switching AEDs within 90 days of enrollment. "Switching" AEDs includes changing from no AED therapy to therapy, discontinuing a current AED therapy, or changing to a different AED therapy.
* Any medical, psychiatric, or other condition that, in the judgment of the investigator, is a contraindication to protocol participation or impairs ability to give informed consent.
Minimum Eligible Age
14 Years
Maximum Eligible Age
45 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Emmes Company, LLC
INDUSTRY
Sponsor Role
collaborator
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Sponsor Role
collaborator
Stanford University
OTHER
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Kimford Jay Meador
Professor
Responsibility Role
PRINCIPAL_INVESTIGATOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Kimford J Meador, M.D.
Role: PRINCIPAL_INVESTIGATOR
Stanford University
Page B Pennell, M.D.
Role: PRINCIPAL_INVESTIGATOR
University of Pittsburgh
Abigail Matthews, PhD
Role: PRINCIPAL_INVESTIGATOR
The Emmes Company, LLC
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Alabama Birmingham Hospital- UAB
Birmingham, Alabama, United States
Site Status
University of Arizona - University Medical Center
Tucson, Arizona, United States
Site Status
Keck Hospital of the University of Southern California
Los Angeles, California, United States
Site Status
Stanford University
Stanford, California, United States
Site Status
University of Miami Hospital - University of Miami School of Medicine
Miami, Florida, United States
Site Status
Emory University School of Medicine
Atlanta, Georgia, United States
Site Status
Medical College of Georgia at Georgia Regents University
Augusta, Georgia, United States
Site Status
Northwestern Memorial Hospital-Northwestern University Feinberg School of Medicine
Chicago, Illinois, United States
Site Status
John Hopkins Bayview Medical Center
Baltimore, Maryland, United States
Site Status
Brigham & Women's Hospital - Harvard
Boston, Massachusetts, United States
Site Status
Henry Ford Hospital
Detroit, Michigan, United States
Site Status
Minnesota Epilepsy Group
Roseville, Minnesota, United States
Site Status
North Shore Jewish Medical Center
Manhasset, New York, United States
Site Status
New York University School of Medicine
New York, New York, United States
Site Status
Columbia University Medical Center/NY Presbyterian Hospital
New York, New York, United States
Site Status
Wake Forest Baptist Health-Wake Forest University School of Medicine
Winston-Salem, North Carolina, United States
Site Status
University of Cincinnati UC Health University Hospital
Cincinnati, Ohio, United States
Site Status
Geisinger Medical Center
Danville, Pennsylvania, United States
Site Status
University of Pittsburgh Medical Center
Pittsburgh, Pennsylvania, United States
Site Status
University of Washington Medical Center
Seattle, Washington, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Meador KJ, Cohen MJ, Loring DW, Matthews AG, Brown C, Robalino CP, Carmack A, Birnbaum AK, Voinescu PE, Gerard EE, Kalayjian LA, Gedzelman ER, Hanna J, Cavitt J, Sam M, Hwang S, Pack AM, French JA, Tsai JJ, Taylor C, Pennell PB; Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) Investigator Group. Neuropsychological Outcomes in 6-Year-Old Children of Women With Epilepsy: A Prospective Nonrandomized Clinical Trial. JAMA Neurol. 2025 Jan 1;82(1):30-39. doi: 10.1001/jamaneurol.2024.3982.
Reference Type
DERIVED
Meador KJ, Cohen MJ, Loring DW, Matthews AG, Brown CA, Robalino C, Carmack A, Sumners S, Birnbaum AK, Kalayjian LA, Gedzelman E, Voinescu PE, Gerard EE, Hanna J, Cavitt J, Sam M, Hwang ST, Pack AM, Tsai JJ, Pennell PB; Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs Investigator Group. Association of Prenatal Exposure to Antiseizure Medications With Creative and Executive Function at Age 4.5 Years. Neurology. 2024 Jun 25;102(12):e209448. doi: 10.1212/WNL.0000000000209448. Epub 2024 May 29.
Reference Type
DERIVED
Gerard EE, Meador KJ, Robalino CP, Brown CA, Matthews AG, Voinescu PE, Kalayjian LA, Gedzelman E, Hanna J, Cavitt J, Sam M, French JA, Pack AM, Hwang ST, Tsai JJ, Taylor C, Pennell PB; MONEAD Investigator Study Group. Initiation and Duration of Breastfeeding in the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs Study. Neurology. 2023 Nov 27;101(22):e2266-e2276. doi: 10.1212/WNL.0000000000207812.
Reference Type
DERIVED
Meador KJ, Stowe ZN, Brown C, Robalino CP, Matthews AG, Kalayjian LA, Voinescu PE, Gerard EE, Penovich P, Gedzelman ER, Cavitt J, Pennell PB; MONEAD Investigator Group. Prospective Cohort Study of Depression During Pregnancy and the Postpartum Period in Women With Epilepsy vs Control Groups. Neurology. 2022 Oct 11;99(15):e1573-e1583. doi: 10.1212/WNL.0000000000200958. Epub 2022 Aug 17.
Reference Type
DERIVED
Toprani S, Meador KJ, Robalino CP, Brown CA, Matthews AG, Gerard EE, Penovich P, Gedzelman E, Cavitt J, Hwang ST, Kalayjian LA, Sam M, Pack A, Pennell PB; MONEAD. Effect of Epilepsy on Sleep Quality During Pregnancy and Postpartum. Neurology. 2022 Oct 10;99(15):e1584-e1597. doi: 10.1212/WNL.0000000000200959.
Reference Type
DERIVED
Meador KJ, Cohen MJ, Loring DW, May RC, Brown C, Robalino CP, Matthews AG, Kalayjian LA, Gerard EE, Gedzelman ER, Penovich PE, Cavitt J, Hwang S, Sam M, Pack AM, French J, Tsai JJ, Pennell PB; Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs Investigator Group. Two-Year-Old Cognitive Outcomes in Children of Pregnant Women With Epilepsy in the Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs Study. JAMA Neurol. 2021 Aug 1;78(8):927-936. doi: 10.1001/jamaneurol.2021.1583.
Reference Type
DERIVED
Pennell PB, French JA, May RC, Gerard E, Kalayjian L, Penovich P, Gedzelman E, Cavitt J, Hwang S, Pack AM, Sam M, Miller JW, Wilson SH, Brown C, Birnbaum AK, Meador KJ; MONEAD Study Group. Changes in Seizure Frequency and Antiepileptic Therapy during Pregnancy. N Engl J Med. 2020 Dec 24;383(26):2547-2556. doi: 10.1056/NEJMoa2008663.
Reference Type
DERIVED
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol and Informed Consent Form
Related Links
Access external resources that provide additional context or updates about the study.
https://web.emmes.com/study/monead/
MONEAD Study Website
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IRB00060793
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
Birth Defects Associated With Exposure to Lamotrigine in Pregnancy (EUROCAT)
NCT01055327
COMPLETED
Premenstrual Dysphoric Disorder and Antiepileptic Drugs
NCT00612235
COMPLETED
Lamotrigine Pregnancy Registry (LAM05)
NCT01064297
COMPLETED
Pharmacokinetics of Anti-epileptic Drugs in Obese Children
NCT02993861
COMPLETED
Epilepsy Birth Control Registry
NCT01097837
UNKNOWN
Counseling on the Interaction of Hormonal Contraceptives and Antiepileptics
NCT02485756
COMPLETED
NA
Application of Novel Diagnostic and Therapeutical Methods in Epilepsy and Neurodevelopmental Abnormalities in Children.
NCT03486366
UNKNOWN
NA
Pediatric Epilepsy Study
NCT00050947
COMPLETED
PHASE3
Phenylbutyrate for Monogenetic Developmental and Epileptic Encephalopathy
NCT04937062
ACTIVE_NOT_RECRUITING
EARLY_PHASE1
A Study to Investigate LP352 in Children and Adults With Developmental and Epileptic Encephalopathy (DEE)
NCT06908226
ENROLLING_BY_INVITATION
PHASE3
Open-label Study of Cenobamate Monotherapy in Adult Subjects With Newly Diagnosed or Recurrent Partial-Onset Epilepsy
NCT06453213
ACTIVE_NOT_RECRUITING
PHASE4
A Study to Look at Antiepileptic Drug Levels While on Lamictal or Depakote With or Without an Oral Contraceptive
NCT00296413
COMPLETED
Clinical-genetic Investigations in Children With Early Infantile Epilepsies
NCT01357707
COMPLETED
Precision Medicine in the Treatment of Epilepsy
NCT05450822
RECRUITING
Hormone Profiles in Adults With Newly Diagnosed Epilepsy
NCT00137709
UNKNOWN
PHASE4
European Non-interventional Study on Refractory Epilepsy With Developmental Delay
NCT04398667
TERMINATED
Memantine for Epileptic Encephalopathy
NCT03779672
COMPLETED
PHASE4
Pharmacokinetics, Efficacy, and Safety of Perampanel Oral Suspension on Seizure Frequency in Pediatric Subjects Maintained on One to Three Stable Antiepileptic Drugs
NCT01527006
COMPLETED
PHASE2
A Prospective, Remote Observational Study in Pediatric Participants With Early-Onset SCN2A-Developmental and Epileptic Encephalopathy
NCT05407727
COMPLETED
A Study of Divalproex Sodium in Children With ASD and Epileptiform EEG
NCT01170325
WITHDRAWN
PHASE2
Low-Glycemic (LGI) Diet in Pregnant People With Epilepsy
NCT06175247
NOT_YET_RECRUITING
NA
A Phase 3, Placebo-Controlled Study to Investigate LP352 in Children and Adults With Dravet Syndrome (DS)
NCT06660394
RECRUITING
PHASE3
Pediatric Epilepsy Study
NCT00050934
COMPLETED
PHASE3
A Cohort Study on the Prognosis of Neonatal KCNQ2 Gene-associated Epileptic Encephalopathy
NCT03934268
UNKNOWN
Measurement Of Serum Levels Of Two Antiepileptic Drugs During Conversion In Patients With Epilepsy
NCT00043914
COMPLETED
PHASE4